Ouch! Novo Nordisk fails in Phase III

26/08/2015 - 2 minutes

Novo Nordisk joins UCB and gets knocked down by its drug’s final clinical trial. Liraglutide, the already approved adjunct therapy for people with type 2 diabetes won’t reach out to type 1 diabetes.

Novo Nordisk can look at a 90-year long history of improving the lives of diabetes patients. However, the phase IIIa trial that tested several doses of liraglutide as an ‘add-on’ to insulin treatment was a lead balloon.

Liraglutide is a once-daily human analog of the naturally occurring hormone Glucagon-Like Peptide-1. It stimulates the release of insulin only when glucose levels become too high, suppressing the glucagon production by the liver and by inhibiting appetite. The compound is approved for the treatment of type 2 diabetes, and Novo hoped to expand its application to patients suffering from type 1 diabetes.

 

But no chance, the results are disappointing. Only two out of three doses reached the primary objective. They improved HbA1c –  a value to measure the blood glucose level –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member